Is 37 years old a common age for advanced ovarian cancer diagnosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is 37 Years Old a Common Age for Advanced Ovarian Cancer?

No, 37 years old is not a common age for advanced ovarian cancer—ovarian cancer is predominantly a disease of older, postmenopausal women, with over 80% of cases diagnosed in women over 50 years and a median age at diagnosis of 61-63 years. 1, 2

Age Distribution of Ovarian Cancer

Epithelial ovarian cancer, which represents approximately 90% of all ovarian cancers and most commonly presents in advanced stages, has a clear age predilection: 2

  • The majority (>80%) of epithelial ovarian cancer cases are diagnosed in women over 50 years of age 1
  • The average/median age at diagnosis is 61-63 years 1, 2
  • The incidence rate is dramatically lower in younger women: 9.4 per 100,000 for those under 65 compared to 54.8 per 100,000 for those 65 years and older 3

Ovarian Cancer Types in Younger Women

While advanced epithelial ovarian cancer at age 37 is uncommon, certain ovarian cancer subtypes do have a predilection for younger women: 4

Nonepithelial ovarian cancers (which make up less than 10% of all ovarian cancers) are more likely in younger patients: 1

  • Germ cell tumors occur more commonly in women between ages 10-30 years 1
  • Sex cord stromal tumors can occur in younger women and are more likely to be found at early stage 1
  • These nonepithelial cancers generally carry a better prognosis and may be treated with conservative surgeries in reproductive-age women 1

Among epithelial subtypes, low-grade serous carcinoma and mucinous carcinoma may occur in younger women more frequently than high-grade serous carcinoma 4

The Hereditary Exception

The critical exception is hereditary ovarian cancer: 1

  • Women with hereditary ovarian cancer (BRCA1/2 mutations) tend to develop the disease approximately 10 years earlier than women with non-hereditary ovarian cancer 1
  • BRCA1 mutations confer a 15%-45% lifetime risk of ovarian cancer, while BRCA2 mutations confer a 10%-20% lifetime risk 1
  • Twenty percent or more of ovarian cancers are genetically inherited, predominantly linked to BRCA1/2 gene variants 1, 2
  • Importantly, 44% of patients with high-grade serous ovarian cancer and a germline BRCA mutation did not report a family history of cancer 1

Clinical Implications

When encountering advanced ovarian cancer in a 37-year-old woman, you should: 1

  • Strongly consider genetic testing for BRCA1/2 mutations regardless of family history, as nearly half of BRCA mutation carriers lack a reported family history 1
  • Consider Lynch syndrome testing, particularly if the histology is endometrioid or clear-cell carcinoma 1
  • Recognize that while uncommon, this presentation is not impossible and warrants the same aggressive treatment approach as in older women 3

Critical pitfall to avoid: Do not dismiss concerning ovarian masses in younger women simply because "ovarian cancer is a disease of older women"—while statistically uncommon, hereditary cases and certain subtypes do occur in this age group and require prompt evaluation. 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ovarian Cancer: A Review.

JAMA, 2025

Research

Treatment of ovarian cancer in young women.

Clinical obstetrics and gynecology, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.